Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityOther Non-Current LiabilitiesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Goldenwell Biotech (GWLL) Total Non-Current Liabilities (2022 - 2025)

Goldenwell Biotech's Total Non-Current Liabilities history spans 4 years, with the latest figure at $125983.0 for Q3 2025.

  • For Q3 2025, Total Non-Current Liabilities rose 879.26% year-over-year to $125983.0; the TTM value through Sep 2025 reached $125983.0, up 879.26%, while the annual FY2024 figure was $82183.0, 11.3% up from the prior year.
  • Total Non-Current Liabilities reached $125983.0 in Q3 2025 per GWLL's latest filing, down from $148883.0 in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $148883.0 in Q2 2025 to a low of -$20366.0 in Q1 2024.
  • Average Total Non-Current Liabilities over 4 years is $39129.5, with a median of $29126.0 recorded in 2022.
  • Peak YoY movement for Total Non-Current Liabilities: plummeted 1544.4% in 2024, then surged 915.04% in 2025.
  • A 4-year view of Total Non-Current Liabilities shows it stood at $20000.0 in 2022, then soared by 269.18% to $73837.0 in 2023, then increased by 11.3% to $82183.0 in 2024, then soared by 53.3% to $125983.0 in 2025.
  • Per Business Quant, the three most recent readings for GWLL's Total Non-Current Liabilities are $125983.0 (Q3 2025), $148883.0 (Q2 2025), and $84283.0 (Q1 2025).